The Role of Chemoprevention of Colorectal Cancer with 5-Aminosalicylates in Ulcerative Colitis

被引：13
|
作者：
Herfarth, Hans [1 ]
机构：
[1] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA
来源：
DIGESTIVE DISEASES | 2012年 / 30卷
关键词：
Anti-inflammatory agents; Non-steroidal/therapeutic use; Mesalamine; Colorectal cancer; Ulcerative colitis; Crohn's disease; Inflammatory bowel disease; INFLAMMATORY-BOWEL-DISEASE; RISK-FACTORS; RANDOMIZED-TRIAL; NEOPLASIA; MESALAZINE; DYSPLASIA; THERAPY; PREVENT; ACID; ADENOMAS;
D O I：
10.1159/000341894
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
5-aminosalicylates (5-ASA) are widely used to treat patients with ulcerative colitis. Experimental data suggest that these agents can potentially be used in a chemopreventive fashion to inhibit the development of colitis-associated colorectal cancer (CRC); however, observational studies investigating a possible risk reduction of CRC by 5-ASA therapy have revealed conflicting results. Currently, it appears that 5-ASA have no or only a very limited effect as a deterrence against CRC. Thus, a general recommendation for long-term use of 5-ASA solely for chemopreventive measures is not warranted. Copyright (c) 2012 S. Karger AG, Basel
引用
收藏
页码：55 / 59
页数：5
相关论文
共 50 条
  • [1] Cost Effectiveness of Ulcerative Colitis Surveillance in the Setting of 5-Aminosalicylates
    Rubenstein, Joel H.
    Waljee, Akbar K.
    Jeter, Joanne M.
    Velayos, Fernando S.
    Ladabaum, Uri
    Higgins, Peter D. R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (09): : 2222 - 2232
  • [2] Medical Management of Ulcerative Colitis with a Specific Focus on 5-Aminosalicylates
    Freeman, Hugh James
    CLINICAL MEDICINE INSIGHTS-GASTROENTEROLOGY, 2012, 5 : 77 - 83
  • [3] 5-aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis
    Walker, AM
    Szneke, P
    Bianchi, LA
    Field, LG
    Sutherland, LR
    Dreyer, NA
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1997, 92 (05): : 816 - 820
  • [4] High versus low doses of 5-aminosalicylates on duration of time until development of colorectal cancer in patients with ulcerative colitis
    Carriere, Vernon J.
    Oster, Robert A.
    Gutierrez, Alexandra
    GASTROENTEROLOGY, 2008, 134 (04) : A291 - A292
  • [5] 5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-Analysis
    Zhao, Li-Na
    Li, Jie-Yao
    Yu, Tao
    Chen, Guang-Cheng
    Yuan, Yu-Hong
    Chen, Qi-Kui
    PLOS ONE, 2014, 9 (04):
  • [6] 5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?
    Desreumaux, P
    Romano, O
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (05): : 509 - 509
  • [7] Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
    Ford, Alexander C.
    Achkar, Jean-Paul
    Khan, Khurram J.
    Kane, Sunanda V.
    Talley, Nicholas J.
    Marshall, John K.
    Moayyedi, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04): : 601 - 616
  • [8] Chemoprevention of colorectal cancer in ulcerative colitis
    Thomson, A
    INTERNAL MEDICINE JOURNAL, 2006, 36 (08) : 540 - 540
  • [9] Chemoprevention of colorectal cancer in ulcerative colitis
    Victoria J. Croog
    Thomas A. Ullman
    Steven H. Itzkowitz
    International Journal of Colorectal Disease, 2003, 18 : 392 - 400
  • [10] Chemoprevention of colorectal cancer in ulcerative colitis
    Croog, VJ
    Ullman, TA
    Itzkowitz, SH
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2003, 18 (05) : 392 - 400
12345